**BRANDON J. MCMAHON, MD**

Associate Professor of Medicine, University of Colorado School of Medicine

Business Address: University of Colorado, Anschutz Cancer Pavilion, 1665 Aurora Ct, Aurora, CO 80045

**EDUCATION**

May 1997 Boston College, Chestnut Hill, MA

Bachelor of Science, Chemistry; *Summa Cum Laude*

May 2001 SUNY-Upstate Medical University, Syracuse, NY

 M.D.; *AOA*

* 1. University of Rochester Medical Center, Strong Memorial Hospital

Rochester, NY

Internship, Internal Medicine

* 1. University of Rochester Medical Center, Strong Memorial Hospital

Rochester, NY

Residency, Internal Medicine

* 1. University of Rochester Medical Center, Strong Memorial Hospital

Rochester, NY

Fellowship, Hematology

* 1. American Society of Hematology, Clinical Research Training Institute

Clinical trial design/Heparin-induced thrombocytopenia

**ACADEMIC APPOINTMENTS**

August 2016-present: Associate Professor of Medicine

 University of Colorado School of Medicine

 Aurora, CO 80045

Sept 2014-July 2016: Associate Professor of Medicine

 Northwestern University

 Feinberg School of Medicine

 Chicago, IL

July 2007-June 2014: Assistant Professor of Medicine

 Northwestern University

 Feinberg School of Medicine

 Chicago, IL

July 2004-June 2005: Clinical Instructor of Medicine

 University of Rochester Medical Center

 Department of Medicine

**HONORS, SPECIAL RECOGNITION, AWARDS**

July 1995 Masonic Medical Research Fellowship Award

May 1996 Pfizer Chemistry Research Fellowship Award

Sept. 1996- Boston College Undergraduate Research Fellowship Award

May 1997

May 1997 *Summa Cum Laude*

 Phi Beta Kappa

 Scholar of the College, Boston College

 Merck Index Award, most outstanding work in chemistry

 Dean’s scholar

 Alpha Epsilon Delta and Alpha Sigma Nu honor societies

1997-2001 Clarence Bellinger Scholarship: awarded on academic achievements and moral character

1997 Herkimer Rotary Club Scholarship for Medical Education

April 2001 Alpha Omega Alpha

 SUNY Upstate Medical University, Syracuse, NY

June 2003 Morgan Award: for dedication to teaching and patient care

University of Rochester Dept. of Medicine

June 2004 Jacob Holler Resident Teaching Award

 University of Rochester Dept. of Medicine

* 1. Chief Resident of Internal Medicine

University of Rochester Medical Center

June 2006 Department of Medicine Fellowship Teaching Award

 University of Rochester Medical Center

Aug. 2006 American Society of Hematology Clinical Research Training Institute

June 2008 Department of Medicine Excellence in Teaching Award

Division of Hematology/Oncology Teacher of the Year

 Northwestern University

June 2009 Department of Medicine Excellence in Teaching Award

 Internal Medicine Residency Teaching

 Northwestern University

June 2010 Department of Medicine Excellence in Teaching Award

Division of Hematology/Oncology Teacher of the Year

Northwestern University

June 2010 Department of Medicine Excellence in Teaching Award

 Internal Medicine Residency Teaching

 Northwestern University

May 2012 Department of Medicine Excellence in Teaching Award

 Internal Medicine Residency Teaching

 Northwestern University

March 2013 Feinberg School of Medicine Outstanding Teacher Award

 MS3 Clinical Teaching

 Northwestern University

June 2013 Department of Medicine Excellence in Teaching Award

 Division of Hematology/Oncology Teacher of the Year

 Northwestern University

Sept 2016 Excellence in Medical Student Teaching, 2015-2016

 Northwestern University

June 2017 Faculty Teaching Award, Hematology/Oncology Fellowship

 University of Colorado

Nov 2017 ASH Ambassador Award

 American Society of Hematology

Dec 2018 Outstanding Division of Hematology Clinical Leader

University of Colorado

**MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS**

2004-present American College of Physicians

2006-present American Society of Hematology

2008-present International Society on Thrombosis and Haemostasis

2014-present Hemophilia & Thrombosis Research Society

**MAJOR COMMITTEE AND SERVICE RESPONSIBILITES**

**Institutional Service (University, Hospital):**

January 2018-present Director of Clinical Operations, General Hematology

 University of Colorado

June 2017-present Associate Program Director

 Hematology/Oncology Fellowship Program

 University of Colorado

Nov 2016-present Blood Utilization Review Committee

 University of Colorado Hospital

Sept 2016-present Pulmonary Embolism Response Team

 University of Colorado

Sept 2016-present Hematology fellowship oversight/selection committee

 University of Colorado

July 2015-July 2016 Program Director, Hematology/Oncology Fellowship Program

 Northwestern University Feinberg School of Medicine

January 2014-June ‘15 Associate Director, Hematology/Oncology Fellowship Program

 Northwestern University Feinberg School of Medicine

Nov 2011-July 2016 Medical Director, anticoagulant services

 Northwestern Memorial Hospital, Chicago, IL

2010-2016 Pharmacy & Therapeutics Committee

Northwestern Memorial Hospital

July 2007-2016 Associate Director, Hemophilia Treatment Center

 Northwestern University, Chicago, IL

July 2007-2016 Associate Director, Rube Walker Blood Center

 Northwestern Memorial Hospital, Chicago, IL

August 2014-2016 Pulmonary Embolism Response Team

 Multidisciplinary approach to massive/submassive PE treatment

 Northwestern Memorial Hospital, Chicago, IL

2007-2016 Fellowship selection committee, Northwestern University

* 1. Sickle cell work group, Northwestern Memorial Hospital

2004-2016 Internal Medicine Resident recruitment committee

July 2004-June 2005: Chief Resident of Internal Medicine

 University of Rochester Medical Center

**National Committees, Task Forces, Boards, and Commissions**

January 2018-present American Society of Hematology

 ASH Ambassador Program

January 2016-present National Cancer Center Network (NCCN) Myeloproliferative

 Neoplasms Guidelines Panel

March 2016-present National Cancer Center Network (NCCN) Venous

 Thromboembolism Guidelines Panel

April 2014-2016 Hemophilia and Thrombosis Research Society

 Educational Workshop Committee

October 2013-2016 American Society of Hematology Consult a Colleague Program

 Platelet disorders and thrombosis

2013-2015 American Society of Hematology Scientific Committee on

 Thrombosis and Vascular Biology (Jan 2013-Dec 2015)

2011-2016 National Cancer Center Network (NCCN) Myeloid Growth

Factors Guidelines Panel

**LICENSURE AND BOARD CERTIFCATION**

2016-present: Colorado Medical license

2007-2017: Illinois medical license

2004-2007: New York medical license

August 2004: American Board of Internal Medicine

 Internal Medicine

January 2008: American Board of Internal Medicine

Hematology

**REVIEW AND REFEREE WORK**

2009-present Article reviewer, *Blood*

2011-present Article reviewer, *Bone Marrow Transplantation*

2007-present Article reviewer, *Thrombosis Research*

2007 Article reviewer, *Journal of Thrombosis and Hemostasis*

2011-present Article reviewer, *Leukemia Lymphoma*

**INVITED EXTRAMURAL LECTURES & PRESENTATIONS**

**Local**

January 2018 Hematology Grand Rounds

 University of Colorado

 “Myeloproliferative Neoplasms”

January 2018 Medical Grand Rounds

 University of Colorado

 “Myeloproliferative Neoplasm”

October 2017 Hematology Grand Rounds

 University of Colorado

 “Thrombotic complications in hematologic malignancies”

Sept 2017 Department of Medicine Research Conference

 University of Colorado

 “Role of endothelium in JAK2 positive MPN”

April 2017 Leukemia Lymphoma Society

 Myeloproliferative neoplasms

January 2017 Hematology Grand Rounds

 University of Colorado

 “Updates in BCR-ABL Negative MPN”

Feb 2015 Interventional Radiology Grand Rounds

 Northwestern University, Chicago, IL

 “Anticoagulation in the peri-procedural setting”

April 2014 Grand Rounds, Hospitalist Medicine

 Northwestern University, Chicago, IL

 “Targeted oral anticoagulants in the hospital setting”

Nov 2013 Hematology CME Conference

 University of Colorado Denver

 “Targeted Oral Anticoagulants”

October 2013 Medical Grand Rounds

 Northwestern University

 “Diagnostic and Treatment Challenges in Idiopathic VTE”

March 2013 Cancer Center Grand Rounds

 Robert H. Lurie Cancer Center, Northwestern University

 “Updates in Anticoagulation”

May 2012 Department of Medicine Grand Rounds

 St. Joseph’s Hospital, Chicago, IL

 “Updates in Anticoagulant Therapy”

April 2009 Vascular Biology Seminar, Northwestern University

Lecturer, “Updates in Idiopathic Thrombocytopenic Purpura”

May 2007 Medical Grand Rounds, University of Rochester

 Lecturer/panel discussant: “Sickle cell anemia: transitioning from

 pediatric to adult care”

Dec. 2006 Cancer Center Grand Rounds, James P. Wilmot Cancer Center

 Lecturer: “Heparin Induced Thrombocytopenia”

Oct. 2006 Medical Grand Rounds, University of Rochester

Lecturer/panel discussant: “Evidence-based review of safety & efficacy of anticoagulation and IVC filters in the management of venothromboembolic disease”

Feb. 2005 Medical Grand Rounds, University of Rochester

Lecturer: “Nectrozing fasciitis and disseminated intravascular coagulation”

**Regional**

July 2018 54th Annual Internal Medicine Conference

 Estes Park, CO

 “Myeloproliferative Neoplasms: Identification and Management”

January 2017 ASH Updates

 Denver, CO

 “Clinical Conundrums in Venous Thromboembolism”

October 2015 Midwest Hospital Medicine Conference

 Chicago, IL

 “Thrombocytopenia and HIT in Hospitalized Patients”

March 2014 Illinois Medical Oncology Society Meeting

 Chicago, IL

 “Targeted oral anticoagulants in clinical practice”

Jan 2014 Highlights from the American Society of Hematology Annual Meeting

 Updates in Benign Hematology

 Chicago, IL

October 2013 Medical Updates CME talk

 Wentworth-Douglas Hospital, Dover, NH

 “Advances in VTE Treatment”

October 2013 9th Annual Midwest Hospital Medicine Conference

 Chicago, IL

 “Perioperative Management of New Oral Anticoagulants”

Jan 2008 Year in Internal Medicine (talk):

“Duration of anticoagulation in idiopathic venous thromboembolism”

**National**

May 2018 Understanding MPNs: Understanding Best Care & Treatment Options

 Patient Power forum

Oct 2017 Oral presentation, “Outcomes of Medical Management of Pulmonary Embolism”

 Society of Interventional Radiology, Phoenix, AZ

Oct 2017 Oral presentation, “Acute Management of DVT and Role of DOACs”

 Society of Interventional Radiology, Phoenix, AZ

August 2015 Yale University, Hematology CME Conference

 New Haven, CT

 “Updates in anticoagulation and thrombosis”

January 2015 University of Chicago, Hematology Seminar

 Chicago, IL

 “Updates in anticoagulation”

March 2012 University of Michigan Hematology Conference

 “Coagulopathy of Liver Disease Revisited”

Dec 2010 Northwestern University Vascular Biology Symposium

 “Utility of D-Dimer in Predicting Recurrence in Idiopathic VTE”

Sept 2009 Heme/Onc Grand Rounds, James P Wilmot Cancer Center,

University of Rochester, Rochester, NY

“Role of Microparticles in Malignancy-Associated Thrombosis”

**International**

Dec 2018 “Myeloproliferative neoplasms: contemporary and future treatment approaches.”

 60th American Society of Hematology Annual Meeting & Exposition, Satellite Symposia

Dec 2018 “TNFα driven inflammation and mitochondrial dysfunction characterize the platelet

 Hyper-reactivity of aging and myeloproliferative neoplasms”

 60th American Society of Hematology Annual Meeting & Exposition (Poster)

June 2018 “Resurrecting response to ruxolitinib: a phase I study testing the combination of

 Ruxolitinib and the PI3K delta inhibitor umbralisib in ruxolitinib-experienced

 Myelofibrosis”

23rd Congress of European Hematology Association (Talk)

Dec 2016 American Society of Hematology (poster)

 “Temporary and permanent inferior vena cava filters in the oncology population”

Dec 2015 American Society of Hematology (poster)

“Disease characteristics and prognosis of MDS presenting with isolated thrombocytopenia”

Dec 2014 American Society of Hematology (poster)

 “Temporary vena cava filters in oncology patients”

Dec 2014 American Society of Hematology (poster)

 “Prevalence, type, & risk factors for bleeding in a large cohort of MPN patients”

Dec 2013 American Society of Hematology (poster)

 “Clinical use of anti-Xa monitoring in malignancy-associated thrombosis”

Dec 2013 American Society of Hematology (poster)

 “Thrombin generation and fibrinolytic activity in microparticles in acute

 promyelocytic leukemia”

Dec 2012 American Society of Hematology (poster)

 “Tissue Factor Bearing Microparticles and Thrombotic Risk in MPN”

May 2012 American Gastroenterological Association (poster)

 “The Utility of HIT Testing in Patients with Cirrhosis”

Dec 2011 American Society of Hematology (talk):

 “ABIM Maintenance of Certification: 2011 Update in Hematology”

Dec 2011 American Society of Hematology (poster):

 “Microparticles in acute promyelocytic leukemia”

July 2011 International Society of Thrombosis & Hemostasis (poster):

 “Tissue factor bearing microparticles are increased in patients with

lymphoma”

July 2011 International Society of Thrombosis & Hemostasis (poster):

 “Microparticles carry active tissue factor & fibrinolytic factors in

 acute promyelocytic leukemia, and are mainly derived from myeloid

cells”

**TEACHING RECORD**

**Administrative Positions**

Nov 2017- Associate Director, Hematology/Oncology Fellowship Program

 University of Colorado School of Medicine

July 2015-July 2016 Program Director, Hematology/Oncology Fellowship Program

 Northwestern University Feinberg School of Medicine

Jan 2014-June ‘15 Associate Director, Hematology/Oncology Fellowship Program

 Northwestern University Feinberg School of Medicine

2015-2016 Course director, weekly CME Hematopathology conference

 Feinberg School of Medicine, Northwestern University

2014-2016 Course director, medical student hematology clinical elective

 Northwestern University Feinberg School of Medicine

**Selected Teaching Activities**

2016-present Course developer, Hematology case review series (weekly)

 University of Colorado

2016-present ABIM Board review in Hematology (1.5 hours/week for 8 weeks)

 Hematology/Oncology fellowship, University of Colorado

2007-present Supervision and bedside teaching of hematology/oncology fellows, inpatient hematology

 consult service and outpatient hematology clinic, both at Northwestern University

(through July 2016) and University of Colorado (Sept 2016-present)

2016-present Outpatient subspecialty clinical training for internal medicine residents

 University of Colorado

2016-present Outpatient subspecialty clinical training, 3rd year medical students

 University of Colorado

2012-2016 ABIM Board review in Hematology

 Hematology/Oncology fellowship, Northwestern University

2014-2016 ABIM Board review in Hematology

 Internal medicine residency program, Northwestern University

2014-2016 Lecturer, hematology unit

 Physician assistant students, Northwestern University

2012-2015 M3 APDX Course: Interpretation of the CBC

 Northwestern University Feinberg School of Medicine

2011-14 3rd year medical student outpatient subspecialty clinical practice

Preceptor

2010 Second Year Medical Student Clinical Skills Course

 Teacher/preceptor

 Northwestern University Feinberg School of Medicine

2009 Learning module contributor, Medical Complication Unit of the

National Transplant Surgery Fellowship Curriculum

“Abnormalities in Hemostasis and Thrombosis in Liver and Renal Transplantation”

2007-2016 Lecturer, Hematology and Cardiovascular sections

Scientific Basis of Medicine (2nd and 3rd year medical students)

Feinberg School of Medicine, Northwestern University

2008-2016 Lecturer, Antiphospholipid Antibody Syndrome (annual series)

 Rheumatology Fellowship, Northwestern University

2007-2016 Formal didactic lectures in Hematology

 Hematology/Oncology fellowship, Northwestern University

2007-2016 Developer and lecturer, Hematology section of Internal Medicine

Resident core lecture series

2007-2016 Internal Medicine Resident morning report faculty discussant

Northwestern University

Feb. 2007 Co-course developer, Hematology section of Internal Medicine Resident core lecture series

* 1. Chief Resident, Internal Medicine:

Daily morning report: case based educational sessions

Daily didactic and bedside teaching sessions for medical residents and students

Procedural supervision

**CLINICAL TRIAL EXPERIENCE**

2018 Site PI, Phase II Itacitinib +/- ruxolitinib in myelofibrosis

 Sponsor: Incyte Corporation

 Site: University of Colorado Comprehensive Cancer Center, Aurora, CO

2017 Site PI, Phase I/II TGR1202 in myelofibrosis & polycythemia vera

 Sponsor: Vanderbilt University

 Site: University of Colorado Comprehensive Cancer Center, Aurora, CO

2015-2016 Co-leader, clinical trial development in Myeloproliferative Neoplasms

 Robert H. Lurie Comprehensive Cancer Center

 Northwestern University, Chicago, IL

2011-2013 Site PI, SPINART study: prophylactic versus on-demand sucrose-formulated

rFVIII therapy in sever Hemophilia A

 Sponsor: Bayer Healthcare AG

 Site: Northwestern University, Chicago, IL

2008-2010 Site PI, MAGELLAN study: Rivaroxaban in hospitalized, medically ill patients

 Sponsor: Bayer Healthcare Pharmaceuticals

 Site: Northwestern University, Chicago, IL

**BIBLIOGRAPHY**

**Journal Articles**

1. Streiff MB; Holmstrom B; Angelini D; Ashrani A; Bockenstedt PL; Chesney C; Fanikos J; Fenninger RB; Fogerty AE; Gao S; Goldhaber SZ; Gundabolu K; Hendrie P; Lee AI; Lee JT; Mann J; **McMahon B**; Millenson MM; Morton C; Ortel T; Ozair S; Paschal R; Shattil S; Siddiqi T; Smock KJ; Soff G; Wang TF; Williams E; Zakarija A; Hammond L; Dwyer MA; Engh AM. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw 2018; 16(11): 1289.
2. Gotlib J, Gerds AT, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Dehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Walsh K, Bergman MA, and Sundar H. Systemic Mastocytosis version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018; 16(12): 1500-1537.
3. Wilberger, A; **McMahon, B**; and Ewalt, M. The power of the partner: defying expectations in a case of a myeloproliferative neoplasm with FGFR1 rearrangement. *Leukemia & Lymphoma* 2018; Oct 2: 1-3 (epub ahead of print).
4. Mesa, RA; Jamieson C; Bhatia R; Deininger MW; Fletcher CD; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; **McMahon B**; Mohan SR; Oh S; Padron E; Papadantonkis N; Pancari P; Podoltsev N; Rampal R; Ranheim E; Reddy V; Rein LAM; Scott B; Snyder DS; Stein BL; Talpaz M; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; and Sundar H. NCCN guidelines insights: Myeloproliferative Neoplasms. J Natl Compr Canc Netw 2017; 15(10): 1193.
5. Waisbren, J; Dinnner, S; Altman, J; Frankfurt, O; Helenowski, I; Gao, J; **McMahon, B**; and Stein, BL. Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. *Int J Hematol*2017; 105(1): 44-51.

1. **McMahon, B** and Kamath, S. Pancytopenia in a patient with hypothyroidism. *JAMA*

2016; 315(15): 1648.

1. Buck, R; Wachsberg, KN; Weaver, AC; Hansen, LO; **McMahon, B**; Dombrowski, L; and O’Leary, K. Survey of provider transfusion practices for oncology patients in an academic medical center. *South Med J* 2016; 109(4): 267-71.
2. Kamath, S and **McMahon, B**. Update in anticoagulation: what IR needs to know. *Semin Intervent Radiol* 2016; 33(2): 122-31.
3. Kaplan JB; Stein BL; **McMahon B**; Giles FJ; and Platanias L. Evolving therapeutic strategies for the classic Philadelphia negative myeloproliferative neoplasms. *EBioMedicine* 2016; 2016; 3: 17-25.

1. Yentz, S; Onwuemene, O; Stein, BL; Cull, E; **McMahon, B**. Clinical use of anti-Xa monitoring in malignancy associated thrombosis. *Thrombosis* 2015; 2015: 126975.
2. **McMahon, B** and Kwaan, HC. Components of the plasminogen-plasmin system as biologic markers for cancer. *Adv Exp Med Biol* 2015; 867: 145-56.
3. Kander, EM; Raza, S; Zhou, Z; Gao, J; Zakarija, A; **McMahon, B**; and Stein, BL. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. *In J Hematol* 2015;102(5): 587-93.
4. Saleiro, D; Mehrotra, S; Kroczynska, B; Beauchamp, E; Lisowski, P; Majchrzak-Kita, B; Bhagat, T; Stein, BL; **McMahon, B**; Altman, JK; Kosciuczuk, E; Baker, D; Jie, C; Jafari, N; Thompson, C; Levine, R; Fish, E; Verma, A; and Platanias, LC. Central role of ULK1 in type I interferon signaling. *Cell Reports* 2015; 11: 605-617.
5. **McMahon, B** and Kwaan, HC. The new or non-vitamin K antagonist oral anticoagulants (NOACs): what we have learned since their debut. *Semin Thromb Hemostasis* 2015; 41: 188-194.
6. Prince, BT; **McMahon, BJ**; Jain, M; and Peters, AT. Meropenem tolerance in a patient with probably fulminant pipercillin-induced immune hemolytic anemia. *J Allergy and Clinical Immunology: In practice* 2015; 3(3): 452-53.
7. Martin, K; Kia, L; Parikh, ND; Kulik, L; and **McMahon, B**. Heparin-induced thrombocytopenia testing is over-utilized in cirrhosis & correlates with poor clinical outcome. *Ann Hepatol* 2014; 13(5): 548-54.
8. Kwaan, HC; **McMahon, BJ**; Hylek, EM. Age-related changes in thrombosis and hemostasis. *Semin Thromb Hemost* 2014; 40(6): 619-20.
9. **McMahon, B** and Kwaan, HC. Thrombocytopenia in older adults. *Semin Thromb Hemostasis* 2014; 40(6): 682-687.
10. Kaur S, Kroczynska B, Sharma B, Sassano A, Arslan AD, Majchrzak-Kita B, Stein BL, **McMahon B**, Altman JK, Su B, Calogero RA, Fish EN, Platanias LC. Critical Roles for Rictor/Sin1 complexes in IFN-dependent gene transcription and generation of antiproliferative properties. *J Biol Chem* 2014; 289: 6581.
11. **McMahon, B**. Meeting report of the 55th American Society of Hematology Meeting: Benign Hematology. *New England Journal of Medicine Journal Watch* Feb 2014; 9 (2): 12.
12. **McMahon, B**. and Martin, K. Successful coronary artery bypass grafting in a patient with severe factor VII deficiency, with minimal use of recombinant factor VIIa. *Haemophilia* 2014; 20(1): e94-7.
13. Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, **McMahon B**, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M. Myeloid growth factors*. J Natl Compr Canc Netw* 2013; 11(10): 1266-90.
14. Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, **McMahon B**, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A, Verma A, Fish EN, Platanias LC. Essential role for the Mnk-pathway in the inhibitory effects of Type I interferons on myeloproliferative neoplasm (MPN) precursors. *J Biol Chem* 2013; 288 (33): 23814-22.
15. Kwaan, HC; Mazar, AP; **McMahon, B**. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye*. Semin Thromb Hemost* 2013; 39 (4): 382-391.
16. **McMahon, B**. Heterogeneity in the myelodysplastic syndromes: moving toward a better understanding. *Leuk Lymphoma* 2013; 54(5): 907-8.
17. Stein, BL; Saraf S.; Sobol, U.; Halpern, A.; Shammo, J.; Rondelli, D.; Michaelis, L.; Odenike, O.; Rademaker, A.; Zakarija, A.; **McMahon, B**.; Spivak, JL; and Moliterno, AR. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. *Leuk Lymphoma* 2013; 54(9): 1989-95.
18. **McMahon, B**. and Stein, BL. Thrombotic and bleeding complications in the classical myeloproliferative neoplasms. *Semin Thromb Hemost* 2013; 39(1): 101-111.
19. **McMahon, B**. and Kwaan, HC. Thrombotic and bleeding complications associated with chemotherapy. *Semin Thromb Hemost* 2012; 38 (8): 808-817.
20. Sharma B.; Joshi, S.; Sassano, A.; Majchrzak, B.; Kaur, S.; Aggarwal, P.; Nabet, B.; Bulic, M.; Stein, B.; **McMahon, B.**; Baker, D.; Fukunaga, R.; Altman, J.; Licht, J.; Fish, E.; and Platanias, L. Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. *Journal of Biological Chemistry* 2012; 287(50): 42352-60.
21. Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, **McMahon B**, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M; National Comprehensive Cancer Network. Myeloid Growth Factors. *J Natl Compr Canc Netw* 2011; 9(8): 914-32.
22. Ruch, J.; **McMahon, B.**; Ramsey, G. and Kwaan, H. Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with Rituximab. *Am J Hematol* 2009: 84(2): 120-22.
23. **McMahon, B.** Malignancy associated thrombosis. *Oncology Issues* 2009; 24: 20-23.
24. Stein, E.; **McMahon, B.**; Kwaan, H.; Altman, J.; Frankfurt, O.; and Tallman, M. The coagulopathy of acute promyelocytic leukaemia revisited. *Best Pract Res Clin Haematol* 2009; 22: 153-63.
25. **McMahon, B.** and Kwaan, H. The plasminogen activator system and cancer. *Pathophysiol Haemost Thromb* 2008; 36: 184-94.
26. Green, D.; **McMahon, B**.; Foiles, N. and Tian, L. Measurement of hemostatic factors in EDTA plasma. *J of Clinical Pathology* 2008: 130 (5): 811-815.
27. Scott, LT; Boorum, M; **McMahon, BJ**; Hagen, S; Mack, J; Blank, J; Wegner, H; and deMeijere, A. A rational chemical synthesis of C60. *Science* 2002; 295 (5559): 1500-03.
28. Antzelevitch, C; Shimizu, W; and **McMahon, B**. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents Torsade de Pointes in models of acquired and congenital long QT syndrome. *J Cardiovasc Electrophysiol* 1999; 10: 154-64.

**Books and Book Chapters**

1. Kwaan, HC and McMahon, B. Abnormalities in the fibrinolysis pathway and clinical implications. In: Abutalib SA et al ed. *Nonmalignant Hematology*. Springer International Publishing, Switzerland; 2016.

1. Stein, BL and **McMahon, B** (editors). *Contemporary Management of Myeloproliferative Neoplasms*. New Delhi: Jaypee Brothers Medical Publishing, 2015. Print.
2. **McMahon, B**. Thrombotic and bleeding complications in myleoproliferative neoplasms. In: Stein, BL & McMahon, B eds. *Contemporary Management of Myeloproliferative Neoplasms*. New Delhi: Jaypee Brothers Medical Publishing; 2015: 52.
3. **McMahon, B**. and Kwaan, H. Components of the plasminogen-plasmin system as biologic markers for cancer. In: Bigelow, D ed. *Advances in Experimental Medicine and Biology*. Springer; 2015: 145.
4. **McMahon, B**. Utility of D-Dimer in predicting recurrence in idiopathic venous thromboembolic disease. In: Eskandari, MK; Morasch, MD; Pearce, WH; and Yao, J eds. *New Findings in Vascular Surgery*. Shelton, CT: People’s Medical Publishing House; 2011: 141.
5. **McMahon, B.** and Kwaan, H. The role of plasminogen-plasmin system in cancer. In: Green, D & Kwaan, HC eds. *Coagulation in Cancer*. New York, NY: Springer Publishing; 2009: 43.
6. **McMahon, B.** and Friedberg, JW. Management of patients with nodular lymphocyte-predominant Hodgkin’s lymphoma. In: Crowther, MA; Ginsberg, J; Scheunemann, HJ; Meyer, RM, and Lottenberg, R eds. *Evidence-Based Hematology*. Oxford, UK: Blackwell Publishing; 2008 372.

**Abstracts**

1. Waisbran, J; Dinner, S; Helenowski, I; Gao, J; **McMahon, B**; Stein, BL. Disease characteristics and prognosis of MDS presenting with isolated thrombocytopenia. *Blood* 2015; 126: 3477.
2. Kwaan, HC; Rego, E; **McMahon, B**; and Weiss, I. Thrombin Generation and Fibrinolytic Activity in Microparticles In Acute Promyelocytic Leukemia Blood 2013; 122:3620.
3. McMahon, B; Stein, B; Onwuemene, O; Cull, E; and Yentz, S. Clinical use of anti-Xa monitoring in malignancy associated thrombosis. *Blood* 2013; 122: 3648.
4. Stein, BL; **McMahon, B**; Weiss, I; Kwaan, HC. Tissue factor bearing microparticles and thrombotic risk in the myeloproliferative neoplasms. *Blood* 2012; 120: 1145.
5. Kwaan, HC.; Rego, E.; **McMahon, B**; Weiss, I; and Marvin, J. Microparticles in acute promyelocytic leukemia. *Blood* 2011; 118: 3346.
6. Stein, BL; **McMahon, B**; Weiss, I; Marvin, J; and Kwaan, HC. Tissue factor bearing microparticles in myeloproliferative neoplasms. *Blood* 2011; 118: 5174.
7. **McMahon, B**; Kwaan, HC; Weiss, I; and Marvin, J. Tissue factor bearing microparticles are increased in non-Hodgkin’s lymphoma, and mostly derived from B-lymphocytes. *Journal of Thrombosis & Haemostasis* 2011; 9 (supplement):186 .
8. Kwaan, HC; Rego, E; **McMahon, B**; Weiss, I; and Marvin, J. Microparticles carry active tissue factor and fibrinolytic factors in acute promyelocytic leukemia and are mostly derived from myeloid cells. *Journal of Thrombosis & Haemostasis* 2011; 9 (supplement): 646.
9. **McMahon, BJ;** Ifthikharuddin, JJ; et al. High incidence of thromboembolic complications and PF4 positivity in patients with ventricular assist devices. *Blood* 2006; 108: 100b.
10. Lyman, GH; **McMahon, B**; Kuderer, NM; Crawford, J; Wolff, D; Culakova, E; Poniewierski, M; Dale, D. A risk model for chemotherapy-induced anemia in cancer patients. *Blood* 2005; 106: 754.
11. Sahasrabudhe, D; **McMahon, B**; Lyman, G; Messing, E; Brasacchio, R. Effect of androgen ablation on bone resorption in prostate cancer. (abstract #1663) *Proc Am Soc Clin Oncol* 22, 2003.